Jay Schmelter (RiverVest)
RiverVest off to the races with $275M to invest in early-stage biotech
RiverVest Venture Partners has closed its largest fund yet, with $275 million to inject into early-stage drug and medical device developers.
The fifth fund …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
